(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/137133 A1

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61P 11/00* (2006.01)
A61K 39/215 (2006.01) *A61P 31/14* (2006.01)

(21) International Application Number:
PCT/IB2021/062127

(22) International Filing Date:
21 December 2021 (21.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/129,395 22 December 2020 (22.12.2020) US
PCT/EP2021/052455 03 February 2021 (03.02.2021) EP
PCT/EP2021/069626 14 July 2021 (14.07.2021) EP
PCT/EP2021/069632 14 July 2021 (14.07.2021) EP

(71) Applicants: **CUREVAC AG** [DE/DE]; Friedrich-Miescher-Str. 15, 72076 Tübingen (DE). **GLAXOSMITHKLINE BIOLOGICALS SA** [BE/BE]; Rue de L'institut 89, B-1330 Rixensart (BE).

(72) Inventors: **ROTH, Nicole**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DE). **MORENO, Diego Chaves**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DK). **GROßE, Hans Wolfgang**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DE). **VAHRENHORST, Dominik**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DE). **RAUCH, Susanne**; c/o IP Department, CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: RNA VACCINE AGAINST SARS-COV-2 VARIANTS




FIG. 8

(57) Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID- 19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

WO 2022/137133 A1

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*